JOURNAL OF SHANGHAI JIAOTONG UNIVERSITY (MEDICAL SCIENCE) ›› 2021, Vol. 41 ›› Issue (11): 1478-1484.doi: 10.3969/j.issn.1674-8115.2021.11.011
• Clinical research • Previous Articles Next Articles
Ya-jie GAO1(), Wen-kun MA1, Cheng-jie GAO2, Yi ZHOU1, Jing-wei PAN1()
Online:
2021-11-28
Published:
2021-12-03
Contact:
Jing-wei PAN
E-mail:13333110348@163.com;jwpan@sjtu.edu.cn
Supported by:
CLC Number:
Ya-jie GAO, Wen-kun MA, Cheng-jie GAO, Yi ZHOU, Jing-wei PAN. Exploration of the predictive value of myocardial strain on ventricular remodeling after acute ST-segment elevation myocardial infarction[J]. JOURNAL OF SHANGHAI JIAOTONG UNIVERSITY (MEDICAL SCIENCE), 2021, 41(11): 1478-1484.
Add to citation manager EndNote|Ris|BibTeX
URL: https://xuebao.shsmu.edu.cn/EN/10.3969/j.issn.1674-8115.2021.11.011
Item | Total (n=47) | LVR group (n=16) | non-LVR group (n=31) | P value |
---|---|---|---|---|
Age/year | 58.28±11.59 | 59.06±10.00 | 57.87±12.47 | 0.742 |
Male/n(%) | 41 (87.2) | 13 (81.3) | 28 (90.3) | 0.637 |
BMI/(kg·m-2) | 25.65±4.00 | 25.18±2.34 | 25.89±4.65 | 0.568 |
BSA/m2 | 1.84±0.16 | 1.83±0.18 | 1.84±0.16 | 0.839 |
HR/min-1 | 70.23±11.56 | 76.94±12.98 | 66.77±9.18 | 0.003 |
Follow-up time/month | 12.54±7.00 | 12.29±7.24 | 12.66±6.99 | 0.867 |
Systolic blood pressure/mmHg | 128.02±23.70 | 131.44±25.84 | 126.26±22.75 | 0.484 |
Diastolic blood pressure/mmHg | 77.40±14.12 | 77.06±17.90 | 77.58±12.06 | 0.907 |
Hypertension/n(%) | 29 (61.7) | 10 (62.5) | 19 (61.3) | 0.936 |
Diabetes/n(%) | 16 (34.0) | 7 (43.8) | 9 (29.0) | 0.313 |
Hyperlipidemia/n(%) | 11 (23.4) | 4 (25.0) | 7 (22.6) | 1.000 |
Smoking/n(%) | 23 (48.9) | 7 (43.8) | 16 (51.6) | 0.609 |
Peak hs-cTnI/(μg·L-1) | 61.96±50.75 | 84.40±63.42 | 50.38±39.13 | 0.121 |
Peak proBNP/(ng·L-1) | 986.00 (620.00, 1 762.00) | 1 267.50 (641.25, 1 958.50) | 944.00 (588.00, 1 701.00) | 0.686 |
Culprit vessel | ||||
LAD/n(%) | 43 (91.5) | 15 (93.8) | 28 (90.3) | 1.000 |
LCX/n(%) | 29 (61.7) | 10 (62.5) | 19 (61.3) | 0.936 |
RCA/n(%) | 21 (44.7) | 7 (43.8) | 14 (45.2) | 0.927 |
Medication | ||||
Antiplatelet/n(%) | 34 (72.3) | 11 (68.8) | 23 (74.2) | 0.693 |
Stations/n(%) | 45 (95.7) | 15 (93.8) | 30 (96.8) | 1.000 |
β-blocker/n(%) | 45 (95.7) | 16 (100.0) | 29 (93.6) | 0.541 |
ACEI/ARB/ARNI/n(%) | 37 (78.7) | 12 (75.0) | 25 (80.7) | 0.943 |
Diuretics/n(%) | 22 (46.8) | 8 (50.0) | 14 (45.2) | 0.753 |
Nitrates/n(%) | 15 (31.9) | 5 (31.3) | 10 (32.3) | 0.944 |
CMR parameter | ||||
LVESV/mL | 74.65±25.04 | 66.72±20.09 | 78.75±26.62 | 0.119 |
LVSV/mL | 68.74±20.28 | 60.08±11.27 | 73.21±22.50 | 0.034 |
LVEF/% | 49.22±10.60 | 48.14±8.41 | 49.78±11.67 | 0.621 |
LVMI/(g·m-2) | 70.40±13.41 | 76.30±13.35 | 67.36±12.58 | 0.029 |
GLS | -10.15±2.80 | -8.50±2.18 | -11.00±2.73 | 0.003 |
GCS | -12.12±2.70 | -10.82±2.30 | -12.79±2.68 | 0.016 |
GRS | 18.11±4.91 | 15.81±4.30 | 19.30±4.84 | 0.019 |
Tab 1 Comparison of baseline data between the LVR group and the non-LVR group in the model where LVEDV increased by ≥20%
Item | Total (n=47) | LVR group (n=16) | non-LVR group (n=31) | P value |
---|---|---|---|---|
Age/year | 58.28±11.59 | 59.06±10.00 | 57.87±12.47 | 0.742 |
Male/n(%) | 41 (87.2) | 13 (81.3) | 28 (90.3) | 0.637 |
BMI/(kg·m-2) | 25.65±4.00 | 25.18±2.34 | 25.89±4.65 | 0.568 |
BSA/m2 | 1.84±0.16 | 1.83±0.18 | 1.84±0.16 | 0.839 |
HR/min-1 | 70.23±11.56 | 76.94±12.98 | 66.77±9.18 | 0.003 |
Follow-up time/month | 12.54±7.00 | 12.29±7.24 | 12.66±6.99 | 0.867 |
Systolic blood pressure/mmHg | 128.02±23.70 | 131.44±25.84 | 126.26±22.75 | 0.484 |
Diastolic blood pressure/mmHg | 77.40±14.12 | 77.06±17.90 | 77.58±12.06 | 0.907 |
Hypertension/n(%) | 29 (61.7) | 10 (62.5) | 19 (61.3) | 0.936 |
Diabetes/n(%) | 16 (34.0) | 7 (43.8) | 9 (29.0) | 0.313 |
Hyperlipidemia/n(%) | 11 (23.4) | 4 (25.0) | 7 (22.6) | 1.000 |
Smoking/n(%) | 23 (48.9) | 7 (43.8) | 16 (51.6) | 0.609 |
Peak hs-cTnI/(μg·L-1) | 61.96±50.75 | 84.40±63.42 | 50.38±39.13 | 0.121 |
Peak proBNP/(ng·L-1) | 986.00 (620.00, 1 762.00) | 1 267.50 (641.25, 1 958.50) | 944.00 (588.00, 1 701.00) | 0.686 |
Culprit vessel | ||||
LAD/n(%) | 43 (91.5) | 15 (93.8) | 28 (90.3) | 1.000 |
LCX/n(%) | 29 (61.7) | 10 (62.5) | 19 (61.3) | 0.936 |
RCA/n(%) | 21 (44.7) | 7 (43.8) | 14 (45.2) | 0.927 |
Medication | ||||
Antiplatelet/n(%) | 34 (72.3) | 11 (68.8) | 23 (74.2) | 0.693 |
Stations/n(%) | 45 (95.7) | 15 (93.8) | 30 (96.8) | 1.000 |
β-blocker/n(%) | 45 (95.7) | 16 (100.0) | 29 (93.6) | 0.541 |
ACEI/ARB/ARNI/n(%) | 37 (78.7) | 12 (75.0) | 25 (80.7) | 0.943 |
Diuretics/n(%) | 22 (46.8) | 8 (50.0) | 14 (45.2) | 0.753 |
Nitrates/n(%) | 15 (31.9) | 5 (31.3) | 10 (32.3) | 0.944 |
CMR parameter | ||||
LVESV/mL | 74.65±25.04 | 66.72±20.09 | 78.75±26.62 | 0.119 |
LVSV/mL | 68.74±20.28 | 60.08±11.27 | 73.21±22.50 | 0.034 |
LVEF/% | 49.22±10.60 | 48.14±8.41 | 49.78±11.67 | 0.621 |
LVMI/(g·m-2) | 70.40±13.41 | 76.30±13.35 | 67.36±12.58 | 0.029 |
GLS | -10.15±2.80 | -8.50±2.18 | -11.00±2.73 | 0.003 |
GCS | -12.12±2.70 | -10.82±2.30 | -12.79±2.68 | 0.016 |
GRS | 18.11±4.91 | 15.81±4.30 | 19.30±4.84 | 0.019 |
Variable | β | SE | OR | 95%CI | P value |
---|---|---|---|---|---|
HR | -0.070 | 0.035 | 0.932 | 0.871‒0.998 | 0.043 |
GLS | -0.334 | 0.155 | 0.716 | 0.528‒0.971 | 0.031 |
Tab 2 Logistic regression analysis of risk factors for LVR in the model where LVEDV increased by ≥20%
Variable | β | SE | OR | 95%CI | P value |
---|---|---|---|---|---|
HR | -0.070 | 0.035 | 0.932 | 0.871‒0.998 | 0.043 |
GLS | -0.334 | 0.155 | 0.716 | 0.528‒0.971 | 0.031 |
Item | Total (n=47) | LVR group (n=17) | non-LVR group (n=30) | P value |
---|---|---|---|---|
Age/year | 58.28±11.59 | 60.29±10.43 | 57.13±12.21 | 0.375 |
Male/n(%) | 41 (87.2) | 14 (82.4) | 27 (90.0) | 0.764 |
BMI/(kg·m-2) | 25.65±4.00 | 26.09±3.46 | 25.40±4.32 | 0.574 |
BSA/m2 | 1.84±0.16 | 1.85±0.21 | 1.83±0.13 | 0.599 |
HR/min-1 | 70.23±11.56 | 72.47±12.28 | 68.97±11.14 | 0.323 |
Follow-up time/month | 12.54±7.00 | 11.74±3.42 | 12.99±8.41 | 0.413 |
Systolic blood pressure/mmHg | 128.02±23.70 | 127.53±25.11 | 128.30±23.29 | 0.916 |
Diastolic blood pressure/mmHg | 77.40±14.12 | 77.47±16.29 | 77.37±13.03 | 0.981 |
Hypertension/n(%) | 29 (61.7) | 12 (70.6) | 17 (56.7) | 0.345 |
Diabetes/n(%) | 16 (34.0) | 7 (41.2) | 9 (30.0) | 0.437 |
Hyperlipidemia/n(%) | 11 (23.4) | 3 (17.7) | 8 (26.7) | 0.731 |
Smoking/n(%) | 23 (48.9) | 7 (41.2) | 16 (53.3) | 0.423 |
Peak hs-cTnI/(μg·L-1) | 61.96±50.75 | 86.68±62.28 | 47.96±37.21 | 0.035 |
Peak proBNP/(ng·L-1) | 986.00 (620.00, 1 762.00) | 1 571.00 (891.50, 2 643.50) | 930.00 (536.50, 1 589.25) | 0.044 |
Culprit vessel | ||||
LAD/n(%) | 43 (91.5) | 16 (94.1) | 27 (90.0) | 1.000 |
LCX/n(%) | 29 (61.7) | 12 (70.6) | 17 (56.7) | 0.345 |
RCA/n(%) | 21 (44.7) | 7 (41.2) | 14 (46.7) | 0.716 |
Medication | ||||
Antiplatelet/n(%) | 34 (72.3) | 15 (88.2) | 19 (63.3) | 0.135 |
Stations/n(%) | 45 (95.7) | 17 (100.0) | 28 (93.3) | 0.528 |
β-blocker/n(%) | 45 (95.7) | 17 (100.0) | 28 (93.3) | 0.528 |
ACEI/ARB/ARNI/n(%) | 37 (78.7) | 14 (82.4) | 23 (76.7) | 0.931 |
Diuretics/n(%) | 22 (46.8) | 8 (47.1) | 14 (46.7) | 0.979 |
Nitrates/n(%) | 15 (31.9) | 4 (23.5) | 11 (36.7) | 0.547 |
CMR parameter | ||||
LVEDV/mL | 145.52±30.54 | 138.72±28.87 | 149.38±31.25 | 0.255 |
LVSV/mL | 68.74±20.28 | 61.41±23.08 | 72.90±17.58 | 0.061 |
LVEF/% | 49.22±10.60 | 48.54±12.15 | 49.61±9.83 | 0.745 |
LVMI/(g·m-2) | 70.40±13.41 | 75.87±14.70 | 67.30±11.76 | 0.034 |
GLS | -10.15±2.80 | -8.78±2.11 | -10.93±2.87 | 0.010 |
GCS | -12.12±2.70 | -11.25±2.39 | -12.62±2.77 | 0.094 |
GRS | 18.11±4.91 | 16.55±4.45 | 18.99±5.00 | 0.102 |
Tab 3 Comparison of baseline data between the LVR group and the non-LVR group in the model where LVESV increased by ≥15%
Item | Total (n=47) | LVR group (n=17) | non-LVR group (n=30) | P value |
---|---|---|---|---|
Age/year | 58.28±11.59 | 60.29±10.43 | 57.13±12.21 | 0.375 |
Male/n(%) | 41 (87.2) | 14 (82.4) | 27 (90.0) | 0.764 |
BMI/(kg·m-2) | 25.65±4.00 | 26.09±3.46 | 25.40±4.32 | 0.574 |
BSA/m2 | 1.84±0.16 | 1.85±0.21 | 1.83±0.13 | 0.599 |
HR/min-1 | 70.23±11.56 | 72.47±12.28 | 68.97±11.14 | 0.323 |
Follow-up time/month | 12.54±7.00 | 11.74±3.42 | 12.99±8.41 | 0.413 |
Systolic blood pressure/mmHg | 128.02±23.70 | 127.53±25.11 | 128.30±23.29 | 0.916 |
Diastolic blood pressure/mmHg | 77.40±14.12 | 77.47±16.29 | 77.37±13.03 | 0.981 |
Hypertension/n(%) | 29 (61.7) | 12 (70.6) | 17 (56.7) | 0.345 |
Diabetes/n(%) | 16 (34.0) | 7 (41.2) | 9 (30.0) | 0.437 |
Hyperlipidemia/n(%) | 11 (23.4) | 3 (17.7) | 8 (26.7) | 0.731 |
Smoking/n(%) | 23 (48.9) | 7 (41.2) | 16 (53.3) | 0.423 |
Peak hs-cTnI/(μg·L-1) | 61.96±50.75 | 86.68±62.28 | 47.96±37.21 | 0.035 |
Peak proBNP/(ng·L-1) | 986.00 (620.00, 1 762.00) | 1 571.00 (891.50, 2 643.50) | 930.00 (536.50, 1 589.25) | 0.044 |
Culprit vessel | ||||
LAD/n(%) | 43 (91.5) | 16 (94.1) | 27 (90.0) | 1.000 |
LCX/n(%) | 29 (61.7) | 12 (70.6) | 17 (56.7) | 0.345 |
RCA/n(%) | 21 (44.7) | 7 (41.2) | 14 (46.7) | 0.716 |
Medication | ||||
Antiplatelet/n(%) | 34 (72.3) | 15 (88.2) | 19 (63.3) | 0.135 |
Stations/n(%) | 45 (95.7) | 17 (100.0) | 28 (93.3) | 0.528 |
β-blocker/n(%) | 45 (95.7) | 17 (100.0) | 28 (93.3) | 0.528 |
ACEI/ARB/ARNI/n(%) | 37 (78.7) | 14 (82.4) | 23 (76.7) | 0.931 |
Diuretics/n(%) | 22 (46.8) | 8 (47.1) | 14 (46.7) | 0.979 |
Nitrates/n(%) | 15 (31.9) | 4 (23.5) | 11 (36.7) | 0.547 |
CMR parameter | ||||
LVEDV/mL | 145.52±30.54 | 138.72±28.87 | 149.38±31.25 | 0.255 |
LVSV/mL | 68.74±20.28 | 61.41±23.08 | 72.90±17.58 | 0.061 |
LVEF/% | 49.22±10.60 | 48.54±12.15 | 49.61±9.83 | 0.745 |
LVMI/(g·m-2) | 70.40±13.41 | 75.87±14.70 | 67.30±11.76 | 0.034 |
GLS | -10.15±2.80 | -8.78±2.11 | -10.93±2.87 | 0.010 |
GCS | -12.12±2.70 | -11.25±2.39 | -12.62±2.77 | 0.094 |
GRS | 18.11±4.91 | 16.55±4.45 | 18.99±5.00 | 0.102 |
Variable | β | SE | OR | 95%CI | P value |
---|---|---|---|---|---|
Peak hs-cTnI | -0.017 | 0.008 | 0.982 | 0.968‒0.998 | 0.024 |
GLS | -0.304 | 0.149 | 0.738 | 0.551‒0.987 | 0.041 |
Tab 4 Logistic regression analysis of risk factors for LVR in the model where LVESV increased by ≥15%
Variable | β | SE | OR | 95%CI | P value |
---|---|---|---|---|---|
Peak hs-cTnI | -0.017 | 0.008 | 0.982 | 0.968‒0.998 | 0.024 |
GLS | -0.304 | 0.149 | 0.738 | 0.551‒0.987 | 0.041 |
1 | Lepper W, Kamp O, Vanoverschelde JL, et al. Intravenous myocardial contrast echocardiography predicts left ventricular remodeling in patients with acute myocardial infarction[J]. J Am Soc Echocardiogr, 2002, 15(9): 849-856. |
2 | Ahn KT, Song YB, Choe YH, et al. Impact of transmural necrosis on left ventricular remodeling and clinical outcomes in patients undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction[J]. Int J Cardiovasc Imaging, 2013, 29(4): 835-842. |
3 | 邹倩, 周淑丽, 郑甜, 等. 心脏MR组织追踪技术评估心肌梗死后左心室心肌应变的价值[J].中华放射学杂志, 2018, 52(8): 587-592. |
4 | Reindl M, Tiller C, Holzknecht M, et al. Prognostic implications of global longitudinal strain by feature-tracking cardiac magnetic resonance in ST-elevation myocardial infarction[J]. Circ Cardiovasc Imaging, 2019, 12(11): e009404. |
5 | 沈卫峰, 张奇, 张瑞岩. 2015年急性ST段抬高型心肌梗死诊断和治疗指南解析[J]. 国际心血管病杂志, 2015, 42(4): 217-219. |
6 | Legallois D, Hodzic A, Alexandre J, et al. Definition of left ventricular remodelling following ST-elevation myocardial infarction: a systematic review of cardiac magnetic resonance studies in the past decade[J]. Heart Fail Rev, 2020. DOI: 10.1007/s10741-020-09975-3. |
7 | Taylor RJ, Moody WE, Umar F, et al. Myocardial strain measurement with feature-tracking cardiovascular magnetic resonance: normal values[J]. Eur Heart J Cardiovasc Imaging, 2015, 16(8): 871-881. |
8 | Lombardo A, Niccoli G, Natale L, et al. Impact of microvascular obstruction and infarct size on left ventricular remodeling in reperfused myocardial infarction: a contrast-enhanced cardiac magnetic resonance imaging study[J]. Int J Cardiovasc Imaging, 2012, 28(4): 835-842. |
9 | 多国帅, 刘婷, 戴旭. 心脏磁共振组织追踪技术评估冠心病心肌梗死的诊断价值[J]. 磁共振成像, 2018, 9(5): 346-353. |
10 | Altiok E, Tiemann S, Becker M, et al. Myocardial deformation imaging by two-dimensional speckle-tracking echocardiography for prediction of global and segmental functional changes after acute myocardial infarction: a comparison with late gadolinium enhancement cardiac magnetic resonance[J]. J Am Soc Echocardiogr, 2014, 27(3): 249-257. |
11 | Ben Driss A, Ben Driss Lepage C, Sfaxi A, et al. Strain predicts left ventricular functional recovery after acute myocardial infarction with systolic dysfunction[J]. Int J Cardiol, 2020, 307: 1-7. |
12 | Iwahashi N, Kirigaya J, Abe T, et al. Impact of three-dimensional global longitudinal strain for patients with acute myocardial infarction[J]. Eur Heart J Cardiovasc Imaging, 2020. DOI:10.1093/ehjci/jeaa241. |
13 | Wang Q, Tan K, Xia H, et al. Left ventricular metabolic remodeling and accompanied dysfunction in type 2 diabetic patients: a 3D speckle tracking analysis[J]. Echocardiography, 2019, 36(3): 486-494. |
14 | Neizel M, Korosoglou G, Lossnitzer D, et al. Impact of systolic and diastolic deformation indexes assessed by strain-encoded imaging to predict persistent severe myocardial dysfunction in patients after acute myocardial infarction at follow-up[J]. J Am Coll Cardiol, 2010, 56(13): 1056-1062. |
15 | Podlesnikar T, Pizarro G, Fernández-Jiménez R, et al. Left ventricular functional recovery of infarcted and remote myocardium after ST-segment elevation myocardial infarction (METOCARD-CNIC randomized clinical trial substudy)[J]. J Cardiovasc Magn Reson, 2020, 22(1): 44. |
16 | Bière L, Donal E, Terrien G, et al. Longitudinal strain is a marker of microvascular obstruction and infarct size in patients with acute ST-segment elevation myocardial infarction[J]. PLoS One, 2014, 9(1): e86959. |
17 | Manovel A, Dawson D, Smith B, et al. Assessment of left ventricular function by different speckle-tracking software[J]. Eur J Echocardiogr, 2010, 11(5): 417-421. |
18 | Nepper-Christensen L, Lønborg J, Ahtarovski KA, et al. Importance of elevated heart rate in the very early phase of ST-segment elevation myocardial infarction: results from the DANAMI-3 trial[J]. Eur Heart J Acute Cardiovasc Care, 2019, 8(4): 318-328. |
19 | HalIdn J, Jensen JK, MwFagerland, et a1. Cardiac troponin Ⅰ for the prediction of functional recovery and left ventricular remodelling following primary percutaneous coronary intervention for ST-elevation myocardial infarction[J].Heart, 2010, 96(23):1892-1897. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||